ExoVectory awarded Eurostars grant, for development of ex vivo T-cell therapy cancer

We are incredibly happy to be one of the awardees of the prestigious Eurostars grant, part of the European Union Eureka Network (3 year project, total value €1,5Mio). To further develop ExoVectory’s exosome delivery platform to deliver CRISPR-Cas genome-editing machinery into cancer-killing T-cells. We join forces with UMC Utrecht (Pieter Vader lab), Utrecht University (Olivier de Jong lab) and EVerZom France. This brings in unique synergy with regards to exosome engineering, CRISPR-Cas tools and T-cell studies and state-of-the-art knowledge and equipment for clinical-grade productions and upscaling of our exosome products.

Explore our exosome delivery technology or contact ExoVectory about partnerships and investment.